Personalising adherence-enhancing interventions using a smart inhaler in patients with COPD: an exploratory cost-effectiveness analysis

被引:0
|
作者
Job F. M. van Boven
Breda Cushen
Imran Sulaiman
Garrett Greene
Elaine MacHale
Matshediso C. Mokoka
Frank Doyle
Richard B. Reilly
Kathleen Bennett
Richard W. Costello
机构
[1] University of Groningen,Department of General Practice & Elderly Care, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC)
[2] University of Groningen,Department of Pharmacy, Unit of Pharmacoepidemiology & Pharmacoeconomics
[3] Smurfit Building Beaumont Hospital,Royal College of Surgeons in Ireland, Clinical Research Centre
[4] Royal College of Surgeons in Ireland,Department of Psychology, Division of Population Health Sciences
[5] The University of Dublin,Trinity Centre for Bioengineering, Trinity College
[6] Royal College of Surgeons in Ireland,Division of Population Health Sciences
[7] Royal College of Surgeons in Ireland,Department of Respiratory Medicine
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Four inhaler adherence clusters have been identified using the INCA audio device in COPD patients: (1) regular use/good technique, (2) regular use/frequent technique errors, (3) irregular use/good technique, and (4) irregular use/frequent technique errors. Their relationship with healthcare utilization and mortality was established, but the cost-effectiveness of adherence-enhancing interventions is unknown. In this exploratory study, we aimed to estimate the potential cost-effectiveness of reaching optimal adherence in the three suboptimal adherence clusters, i.e., a theoretical shift of clusters 2, 3, and 4 to cluster 1. Cost-effectiveness was estimated over a 5-year time horizon using the Irish healthcare payer perspective. We used a previously developed COPD health-economic model that was updated with INCA trial data and Irish national economic and epidemiological data. For each cluster, interventions would result in additional quality-adjusted life years gained at reasonable investment. Cost-effectiveness was most favorable in cluster 3, with possible cost savings of €845/annum/person.
引用
收藏
相关论文
共 50 条
  • [31] COST-EFFECTIVENESS AND BUDGET IMPACT ANALYSIS OF UMEC/VI FOR THE TREATMENT OF COPD PATIENTS IN COLOMBIA
    Gamboa Garay, O. A.
    Medina Torres, Y. A.
    Gamboa Garay, C. A.
    Bastidas Goyes, A. R.
    Dieleman, S.
    VALUE IN HEALTH, 2017, 20 (05) : A201 - A201
  • [32] COST-EFFECTIVENESS OF SINGLE-INHALER TRIPLE THERAPY (FF/UMEC/VI) VERSUS TIOTROPIUM MONOTHERAPY IN PATIENTS WITH COPD IN THE UK
    Martin, A.
    Shah, D.
    Shukla, S.
    Kendall, R.
    Risebrough, N. A.
    Compton, C.
    Ismaila, A.
    VALUE IN HEALTH, 2022, 25 (01) : S40 - S40
  • [33] COST-EFFECTIVENESS OF ADHERENCE IN NEWLY TREATED TUBERCULOSIS PATIENTS USING DISCRETE EVENT SIMULATION
    Min, S.
    Kwon, S. H.
    Nam, J. H.
    VALUE IN HEALTH, 2022, 25 (01) : S116 - S116
  • [34] Cost-effectiveness analysis of umeclidinium/vilanterol for the management of patients with moderate to very severe COPD using an economic model
    Wilson, Michele R.
    Patel, Jeetvan G.
    Coleman, Amber
    McDade, Cheryl L.
    Stanford, Richard H.
    Earnshaw, Stephanie R.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2017, 12 : 997 - 1008
  • [35] Cost-Effectiveness Analysis of a Once-Daily Single-Inhaler Triple Therapy for Patients with Chronic Obstructive Pulmonary Disease (COPD) Using the FULFIL Trial: A Spanish Perspective
    Schroeder, Melanie
    Benjamin, Nicole
    Atienza, Laura
    Biswas, Chandroday
    Martin, Alan
    Whalen, John D.
    Izquierdo Alonso, Jose Luis
    Riesco Miranda, Juan Antonio
    Jose Soler-Cataluna, Juan
    Huerta, Alicia
    Ismaila, Afisi S.
    INTERNATIONAL JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2020, 15 : 1621 - 1632
  • [36] COST-EFFECTIVENESS ANALYSIS OF THE SMART QUIT CLINIC PROGRAM IN CARDIOVASCULAR DISEASE PATIENTS IN THAILAND
    Grant, A.
    Tan, C. J.
    Wattanasirichaigoon, S.
    Rungruanghiranya, S.
    Thongphiew, A.
    Thavorn, K.
    Chaiyakunapruk, N.
    VALUE IN HEALTH, 2022, 25 (07) : S355 - S355
  • [37] A cost-effectiveness analysis of Navina Smart on adult patients affected by neurogenic bowel dysfunction
    Ruggeri, Matteo
    Signorini, Alessandro
    Caravaggio, Silvia
    Righi, Gabriele
    GLOBAL & REGIONAL HEALTH TECHNOLOGY ASSESSMENT, 2024, 11 : 214 - 222
  • [38] COST-EFFECTIVENESS ANALYSIS OF A SINGLE-INHALER TRIPLE THERAPY (TRELEGYA') VS DUAL COMBINATION AND MULTIPLE-INHALER TRIPLE THERAPY FOR THE TREATMENT OF PATIENTS WITH COPD MODERATE TO VERY-SEVERE
    Balmaceda, C.
    Abbott, T.
    Espinoza, M. A.
    VALUE IN HEALTH, 2020, 23 : S354 - S354
  • [39] COST-EFFECTIVENESS OF A SINGLE-INHALER TRIPLE THERAPY VS A DUAL BRONCHODILATOR FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA
    Schembri, S.
    Schroeder, M.
    Shah, D.
    Martin, A.
    Ndirangu, A.
    Risebrough, N.
    Thrasis, A.
    Bremner, P.
    Haberl, M.
    Ismaila, A.
    RESPIROLOGY, 2020, 25 : 145 - 145
  • [40] COST-EFFECTIVENESS OF A SINGLE-INHALER TRIPLE THERAPY VS A DUAL BRONCHODILATOR FOR PATIENTS WITH CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD) IN AUSTRALIA
    Schembri, S.
    Schroeder, M.
    Shah, D.
    Martin, A.
    Ndirangu, K.
    Risebrough, N.
    Thrasis, A.
    Bremner, P.
    Haberl, M.
    Ismaila, A.
    RESPIROLOGY, 2021, 26 : 119 - 119